Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis

Company Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 57,935 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NEU Stock Analysis - Frequently Asked Questions

How were Neuren Pharmaceuticals' earnings last quarter?

Neuren Pharmaceuticals Limited (ASX:NEU) posted its quarterly earnings data on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 75.51% and a net margin of 60.66%.

What other stocks do shareholders of Neuren Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 12/23/2024

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Chemicals
• Current Symbol: ASX:NEU
• CUSIP: N/A
• CIK: N/A
• Web: www.neurenpharma.com
• Phone: 61 3 9092 0480
• Fax: N/A
• Employees: 2,060
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A$0.93
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $117.29 million
• Net Margins: 60.66%
• Pretax Margin: N/A
• Return on Equity: 75.51%
• Return on Assets: 59.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.42
• Quick Ratio: 31.54

Sales & Book Value

• Annual Sales: $193.34 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 12.46
• Book Value: A$1.72 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 130,070,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 2.13